Sakar Healthcare reported a robust performance for the quarter ended June 30, 2026 (Q1FY27), with profit after tax (PAT) surging 120% year-on-year to ₹1,028.49 lakhs. The Ahmedabad-based pharmaceutical manufacturer recorded consolidated revenue from operations of ₹7,297.25 lakhs, marking a 38% increase compared to ₹5,273.62 lakhs in the corresponding quarter of FY26. This growth trajectory underscores the company’s strengthening position in regulated markets, particularly within its oncology segment.

The Board of Directors approved the unaudited standalone and consolidated financial results on July 24, 2026. The company’s operating efficiency improved significantly, with EBITDA rising 67% year-on-year to ₹2,124.89 lakhs. Consequently, the EBITDA margin expanded to 29% from 24% in Q1FY26. Gross profit also saw a sharp increase of 61% to ₹3,839.03 lakhs, pushing the gross profit margin to 53% from 45% in the previous year’s quarter.

Financial Performance Overview

The following table details Sakar Healthcare’s key consolidated financial metrics for Q1FY27 against the prior year and full-year FY26 figures:

Operational Highlights and Oncology Progress

Sakar Healthcare emphasized its strategic focus on oncology, reporting that it has executed more than 65 oncology product contracts, with over 50 commercial discussions currently underway. The company shared 261 dossiers globally, of which 178 have been submitted and 16 have received Marketing Authorisations (MAs). Specifically, the firm completed 26 EU MA filings, including 15 owned filings, and procured six MAs through partners in Bulgaria and Bosnia. Additional filings were made in the Czech Republic, Croatia, and Portugal.

In terms of regulatory compliance and site approvals, Sakar submitted 33 site variations covering 18 cytotoxic molecules across the EU and the UK, with seven already approved. The company is actively engaged in 33 technology transfer projects for oncology products with major global partners, including Accord-Intas, Torrent (UK and Germany), Emcure, Glenmark, and Zydus. Seven of these projects have received site variation approvals—two in the UK and five in the EU.

In-House API Development

Strengthening its integrated manufacturing capabilities, Sakar developed 21 APIs in-house during the period. This portfolio includes 16 APIs with Written Confirmation, eight commercialised products, and two APIs with CEP approval. Five additional CEP applications are currently in process. Sanjay Shah, Managing Director, stated that the company remains on a strong growth trajectory, driven by the scalability of its oncology platform and the progressive commercialization of its product portfolio. He noted that converting regulatory approvals into commercial launches will further improve capacity utilisation and operating leverage.

Cobra India (Mauritius) Limited has acquired a 2.0462% stake in Sakar Healthcare Limited through open market transactions. The acquisition involved the purchase of 489,026 equity shares, increasing the acquirer's footprint in the pharmaceutical company. The disclosure was filed in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the transaction on June 11, 2026, Cobra India (Mauritius) Limited held 1,469,571 shares, which accounted for 6.4532% of the total share or voting capital. Following the acquisition, the entity's holding adjusted to 980,545 shares, representing 4.4069% of the total share or voting capital. The acquirer clarified that it does not belong to the promoter or promoter group of the target company.

The total equity share capital and total voting capital of Sakar Healthcare Limited remained unchanged at INR 2,22,49,910 before and after the acquisition. The total diluted share or voting capital was also reported at INR 2,22,49,910. Cobra India (Mauritius) Limited stated that there were no warrants or convertible securities acquired as part of this transaction.

Acquisition Details

The filing provided a breakdown of the shareholding changes before and after the transaction:

The mode of acquisition was specified as an open market transaction. Jean-Marc Lesieur, Director of Cobra India (Mauritius) Limited, signed the disclosure submitted to the National Stock Exchange of India Ltd. The target company's shares are listed on the National Stock Exchange of India Limited.